ArticleOncogene2014
Inducible expression of hyperactive Syk in B cells activates Blimp-1-dependent terminal differentiation.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway.Cell communication and signaling : CCS · 2024Article
- Single-cell mass cytometry in immunological skin diseases.Frontiers in immunology · 2024Review
- Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies.Blood cancer discovery · 2023Article
- Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.Nature communications · 2021Article
- Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.Nature genetics · 2021Article
- Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis.JCI insight · 2020Article
- Immunoglobulin expression in the endoplasmic reticulum shapes the metabolic fitness of B lymphocytes.Life science alliance · 2020Article
- Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation.Nature reviews. Immunology · 2019Review
- Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production.Frontiers in immunology · 2019Article
- PI3K-Mediated Blimp-1 Activation Controls B Cell Selection and Homeostasis.Cell reports · 2018Article
- Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.The EMBO journal · 2018Article
- Autoimmunity checkpoints as therapeutic targets in B cell malignancies.Nature reviews. Cancer · 2018Review
- Secreted IgM deficiency leads to increased BCR signaling that results in abnormal splenic B cell development.Scientific reports · 2017Article
- Autonomous membrane IgE signaling prevents IgE-memory formation.Nature immunology · 2016Article
- Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.Biochimica et biophysica acta · 2015Review
- A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-receptor protein tyrosine kinase Syk (spleen tyrosine kinase) is an important mediator of signal transduction in B cells. By acting downstream of the B-cell antigen receptor, Syk promotes signaling pathways involved in proliferation, differentiation and survival of B cells. To study the oncogenic potential of Syk, we generated a mouse model for the inducible expression of the leukemia-derived TEL-Syk fusion protein exhibiting constitutive kinase activity. To achieve B-cell-specific expression of TEL-Syk in adult mice, we used a tamoxifen-inducible Cre mouse line. This study shows that inducible expression of TEL-Syk in B cells leads to transient proliferation and subsequent plasma cell differentiation. However, it does not lead to B-cell transformation. Instead, Syk activation induces the tumor suppressor B-lymphocyte-induced maturation protein-1 (Blimp-1), which interferes with the expression of the antiapoptotic protein Bcl-2. Combined induction of TEL-Syk with transgenic expression of Bcl-2 results in a severe phenotype and plasma cell expansion. Our results suggest that deregulated Syk activity by itself is not sufficient for the transformation of B cells, as downstream effectors, such as Blimp-1, limit the survival and expansion of the activated B cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.